The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Open accessAbstract
Cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which result in impairment of CFTR mRNA and protein expression, function, stability or a combination of these. Although CF leads to multifaceted clinical manifestations, the respiratory disorder represents the major cause of morbidity and mortality of these patients. The life expectancy of CF patients has substantially lengthened due to early diagnosis and improvements in symptomatic therapeutic regimens. Quality of life remains nevertheless limited, as these individuals are subjected to considerable clinical, psychosocial and economic burdens. Since the discovery of the CFTR gene in 1989, tremendous efforts have been made to develop therapies acting more upstream on the pathogenesis cascade, thereby overcoming the underlying dysfunctions caused by CFTR mutations. In this line, the advances in cell-based high-throughput screenings have been facilitating the fast-tracking of CFTR modulators. These modulator drugs have the ability to enhance or even restore the functional expression of specific CF-causing mutations, and they have been classified into five main groups depending on their effects on CFTR mutations: read-through agents, amplifiers, correctors, potentiators and stabilizers. To date, four CFTR modulators have reached the market, and these pharmaceutical therapies are transforming patients’ lives with short- and long-term improvements in clinical outcomes. Such breakthroughs have paved the way for the development of novel CFTR modulators, which are currently under experimental and clinical investigations. Recent insights into the CFTR structure will also be useful for the rational design of next-generation modulator drugs. This review aims to provide a summary of recent developments in CFTR-directed therapeutics. Barriers and future directions are also discussed in order to optimize treatment adherence, identify feasible and sustainable solutions for equitable access to these therapies, and continue to expand the pipeline of novel modulators that may result in effective precision medicine for all individuals with CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Webb, A. K. (2006) · Cited by 4,369
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping
Rommens, J. M., Iannuzzi, M. C., Kerem, B.-S., Drumm, M. L., Melmer, G., Dean, M., Rozmahel, R., Cole, J. L., Kennedy, D., Hidaka, N., et al. (1989) · Science · doi:10.1126/science.2772657 · Cited by 3,253
Nährlich, L., Mainz, J. G., Adams, C., Engel, C., Herrmann, G., Icheva, V., Lauer, J., Deppisch, C., Wirth, A., Unger, K., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350071 · Cited by 2,525
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Welsh, M. J., & Smith, A. E. (1993) · Cell · doi:10.1016/0092-8674(93)90353-r · Cited by 1,485
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
Rowe, S. M., Miller, S., & Sorscher, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043184 · Cited by 1,398
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,234
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE: A CLINICAL AND PATHOLOGIC STUDY
ANDERSEN, D. H. (1938) · American Journal of Diseases of Children · doi:10.1001/archpedi.1938.01980140114013 · Cited by 1,146
PTC124 targets genetic disorders caused by nonsense mutations
Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., et al. (2007) · Nature · doi:10.1038/nature05756 · Cited by 1,137
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., & Riordan, J. R. (1995) · Cell · doi:10.1016/0092-8674(95)90241-4 · Cited by 897
Cystic fibrosis: molecular biology and therapeutic implications
Collins, F. (1992) · Science · doi:10.1126/science.1375392 · Cited by 822
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
Chloride impermeability in cystic fibrosis
Quinton, P. M. (1983) · Nature · doi:10.1038/301421a0 · Cited by 767
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807120 · Cited by 726
Rich, D. P., Anderson, M. P., Gregory, R. J., Cheng, S. H., Paul, S., Jefferson, D. M., McCann, J. D., Klinger, K. W., Smith, A. E., & Welsh, M. J. (1990) · Nature · doi:10.1038/347358a0 · Cited by 708
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis
Wang, X., Venable, J., LaPointe, P., Hutt, D. M., Koulov, A. V., Coppinger, J., Gurkan, C., Kellner, W., Matteson, J., Plutner, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.043 · Cited by 601
Veit, G., Avramescu, R. G., Chiang, A. N., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 580
Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer
Drumm, M. L., Pope, H. A., Cliff, W. H., Rommens, J. M., Marvin, S. A., Tsui, L.-C., Collins, F. S., Frizzell, R. A., & Wilson, J. M. (1990) · Cell · doi:10.1016/0092-8674(90)90398-x · Cited by 576
Boucher, R. C., Stutts, M. J., Knowles, M. R., Cantley, L., & Gatzy, J. T. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112708 · Cited by 575
Dekkers, J. F., Berkers, G., Kruisselbrink, E., Vonk, A., de Jonge, H. R., Janssens, H. M., Bronsveld, I., van de Graaf, E. A., Nieuwenhuis, E. E. S., Houwen, R. H. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8278 · Cited by 548
ABNORMAL ELECTROLYTE COMPOSITION OF SWEAT IN CYSTIC FIBROSIS OF THE PANCREAS
DI SANT'AGNESE, P. A., DARLING, R. C., PERERA, G. A., & SHEA, E. (1953) · Pediatrics · doi:10.1542/peds.12.5.549 · Cited by 546
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 538
Molecular Structure of the Human CFTR Ion Channel
Liu, F., Zhang, Z., Csanády, L., Gadsby, D. C., & Chen, J. (2017) · Cell · doi:10.1016/j.cell.2017.02.024 · Cited by 523
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522
Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., Ballmann, M., Boyle, M. P., Bronsveld, I., Campbell, P. W., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200393 · Cited by 515
Van Goor, F., Straley, K. S., Cao, D., González, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M., et al. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00169.2005 · Cited by 512
Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022170 · Cited by 503
Chloride Conductance Expressed by ΔF508 and Other Mutant CFTRs In Xenopus Oocytes
Drumm, M. L., Wilkinson, D. J., Smit, L. S., Worrell, R. T., Strong, T. V., Frizzell, R. A., Dawson, D. C., & Collins, F. S. (1991) · Science · doi:10.1126/science.1722350 · Cited by 496
Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
Howard, M., Frizzell, R. A., & Bedwell, D. M. (1996) · Nature Medicine · doi:10.1038/nm0496-467 · Cited by 493
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Abnormal Ion Permeation Through Cystic Fibrosis Respiratory Epithelium
Knowles, M. R., Stutts, M. J., Spock, A., Fischer, N., Gatzy, J. T., & Boucher, R. C. (1983) · Science · doi:10.1126/science.6308769 · Cited by 485
Pa, D. S., Rc, D., Perera, G. A., & SHEA, E. (1953) · PubMed · Cited by 472
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 452
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Role of CFTR in epithelial physiology
Saint-Criq, V., & Gray, M. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2391-y · Cited by 433
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Yu, H., Burton, B., Huang, C.-J., Worley, J., Cao, D., Johnson, J. P., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.005 · Cited by 423
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W. M., Du, K., Höhfeld, J., Young, J. C., & Lukacs, G. L. (2010) · Science · doi:10.1126/science.1191542 · Cited by 408
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., & Higgins, M. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.005 · Cited by 394
Rubenstein, R. C., Egan, M. E., & Zeitlin, P. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119788 · Cited by 389
Hisert, K. B., Heltshe, S. L., Pope, C., Jorth, P., Wu, X., Edwards, R. M., Radey, M., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 389
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., Roldan, A., Verkman, A. S., Kurth, M., Simon, A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1253 · Cited by 378
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Lukacs, G. L., & Verkman, A. S. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.003 · Cited by 375
Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00545-7 · Cited by 347
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70100-6 · Cited by 346
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807119 · Cited by 331
Misfolding diverts CFTR from recycling to degradation
Sharma, M., Pampinella, F., Nemes, C., Benharouga, M., So, J., Du, K., Bache, K. G., Papsin, B., Zerangue, N., Stenmark, H., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312018 · Cited by 329
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Cholon, D. M., Quinney, N. L., Fulcher, M. L., Esther, C. R., Das, J., Dokholyan, N. V., Randell, S. H., Boucher, R. C., & Gentzsch, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008680 · Cited by 320
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
Berkers, G., van Mourik, P., Vonk, A. M., Kruisselbrink, E., Dekkers, J. F., de Winter-de Groot, K. M., Arets, H. G. M., Marck-van der Wilt, R. E. P., Dijkema, J. S., Vanderschuren, M. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.068 · Cited by 310
Eckford, P. D. W., Li, C., Ramjeesingh, M., & Bear, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393637 · Cited by 309
Socio-economic burden of rare diseases: A systematic review of cost of illness evidence
Angelis, A., Tordrup, D., & Kanavos, P. (2015) · Health Policy · doi:10.1016/j.healthpol.2014.12.016 · Cited by 306
Ratjen, F., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 294
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., Borot, F., Szollosi, D., Wu, Y.-S., Finkbeiner, W. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008889 · Cited by 287
Managing Cystic Fibrosis: Strategies That Increase Life Expectancy and Improve Quality of Life
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1478ci · Cited by 287
Human Nasal and Tracheo-Bronchial Respiratory Epithelial Cell Culture
Fulcher, M. L., & Randell, S. H. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-62703-125-7_8 · Cited by 284
Ren, H. Y., Grove, D. E., De La Rosa, O., Houck, S. A., Sopha, P., Van Goor, F., Hoffman, B. J., & Cyr, D. M. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0240 · Cited by 284
Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30202-9 · Cited by 273
Konstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D., Huang, X., Lubarsky, B., Rubin, J., Millar, S. J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 259
Volkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.015 · Cited by 258
∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis
Pankow, S., Bamberger, C., Calzolari, D., Martínez-Bartolomé, S., Lavallée-Adam, M., Balch, W. E., & Yates, J. R. (2015) · Nature · doi:10.1038/nature15729 · Cited by 258
Du, M., Liu, X., Welch, E. M., Hirawat, S., Peltz, S. W., & Bedwell, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711795105 · Cited by 256
Structural identification of a hotspot on CFTR for potentiation
Liu, F., Zhang, Z., Levit, A., Levring, J., Touhara, K. K., Shoichet, B. K., & Chen, J. (2019) · Science · doi:10.1126/science.aaw7611 · Cited by 253
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
Hutt, D. M., Herman, D., Rodrigues, A. P. C., Noel, S., Pilewski, J. M., Matteson, J., Hoch, B., Kellner, W., Kelly, J. W., Schmidt, A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.275 · Cited by 252
Conformational Changes of CFTR upon Phosphorylation and ATP Binding
Zhang, Z., Liu, F., & Chen, J. (2017) · Cell · doi:10.1016/j.cell.2017.06.041 · Cited by 252
Pulmonary medication adherence and health-care use in cystic fibrosis
Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A. (2014) · Chest · doi:10.1378/chest.13-1926 · Cited by 250
Sermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., Vermeulen, F., Leal, T., Mogenet, A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0137oc · Cited by 248
Molecular structure of the ATP-bound, phosphorylated human CFTR
Zhang, Z., Liu, F., & Chen, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815287115 · Cited by 246
Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
Heltshe, S. L., Mayer-Hamblett, N., Burns, J. L., Khan, U., Baines, A., Ramsey, B. W., & Rowe, S. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu944 · Cited by 239
Sawicki, G. S., McKone, E. F., Pasta, D. J., Millar, S. J., Wagener, J. S., Johnson, C. A., & Konstan, M. W. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0578oc · Cited by 236
Wilschanski, M., Zielenski, J., Markiewicz, D., Tsui, L.-C., Corey, M., Levison, H., & Durie, P. R. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70157-5 · Cited by 235
ASSEMBLY OF FUNCTIONAL CFTR CHLORIDE CHANNELS
Riordan, J. R. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.032003.154107 · Cited by 230
Ramos, K. J., Smith, P. J., McKone, E. F., Pilewski, J. M., Lucy, A., Hempstead, S. E., Tallarico, E., Faro, A., Rosenbluth, D. B., Gray, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.002 · Cited by 227
Haardt, M., Benharouga, M., Lechardeur, D., Kartner, N., & Lukacs, G. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21873 · Cited by 218
Jih, K.-Y., & Hwang, T.-C. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215982110 · Cited by 216
Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210394 · Cited by 214
McKone, E. F., Borowitz, D., Drevinek, P., Griese, M., Konstan, M. W., Wainwright, C., Ratjen, F., Sermet-Gaudelus, I., Plant, B., Munck, A., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70218-8 · Cited by 211
PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy
Osman, G., Rodriguez, J., Chan, S. Y., Chisholm, J., Duncan, G., Kim, N., Tatler, A. L., Shakesheff, K. M., Hanes, J., Suk, J. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.001 · Cited by 208
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
Wilschanski, M., Miller, L. L., Shoseyov, D., Blau, H., Rivlin, J., Aviram, M., Cohen, M., Armoni, S., Yaakov, Y., Pugatch, T., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00120910 · Cited by 205
Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate
Zeitlin, P. L., Diener-West, M., Rubenstein, R. C., Boyle, M. P., Lee, C. K. K., & Brass-Ernst, L. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0639 · Cited by 194
Zhang, L., Button, B., Gabriel, S. E., Burkett, S., Yan, Y., Skiadopoulos, M. H., Dang, Y. L., Vogel, L. N., McKay, T., Mengos, A., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000155 · Cited by 194
Stephenson, A. L., Sykes, J., Stanojevic, S., Quon, B. S., Marshall, B. C., Petren, K., Ostrenga, J., Fink, A. K., Elbert, A., & Goss, C. H. (2017) · Annals of Internal Medicine · doi:10.7326/m16-0858 · Cited by 192
Sun, X., Yi, Y., Yan, Z., Rosen, B. H., Liang, B., Winter, M. C., Evans, T. I. A., Rotti, P. G., Yang, Y., Gray, J. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7531 · Cited by 188
Simpson, J. C., Joggerst, B., Laketa, V., Verissimo, F., Cetin, C., Erfle, H., Bexiga, M. G., Singan, V. R., Hériché, J.-K., Neumann, B., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2510 · Cited by 186
Swiatecka-Urban, A., Brown, A., Moreau-Marquis, S., Renuka, J., Coutermarsh, B., Barnaby, R., Karlson, K. H., Flotte, T. R., Fukuda, M., Langford, G. M., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508944200 · Cited by 184
Donaldson, S. H., Pilewski, J. M., Griese, M., Cooke, J., Viswanathan, L., Tullis, E., Davies, J. C., Lekstrom-Himes, J. A., & Wang, L. T. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0717oc · Cited by 183
Du, M., Jones, J. R., Lanier, J., Keeling, K. M., Lindsey, R. J., Tousson, A., Bebök, Z., Whitsett, J. A., Dey, C. R., Colledge, W. H., et al. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0363-1 · Cited by 181
Classification of CFTR mutation classes
Marson, F. A. L., Bertuzzo, C. S., & Ribeiro, J. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30188-6 · Cited by 181
CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis
Lopes-Pacheco, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00275 · Cited by 180
Self-citationBrazilian guidelines for the diagnosis and treatment of cystic fibrosis
Athanazio, R. A., Filho, L. V. R. F. D. S., Vergara, A. A., Ribeiro, A. F., Riedi, C. A., Procianoy, E. D. F. A., Adde, F. V., Reis, F. J. C., Ribeiro, J. D., Torres, L. A. G. M. M., et al. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000000065 · Cited by 179
Norez, C., Noël, S., Wilke, M., Bijvelds, M. J. C., Jorna, H., Melin‐Heschel, P., de Jonge, H. R., & Becq, F. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.010 · Cited by 169
Milla, C. E., Ratjen, F., Marigowda, G., Liu, F., Waltz, D., & Rosenfeld, M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1754oc · Cited by 168
Nonsense-mediated mRNA decay: Inter-individual variability and human disease
Nguyen, L. S., Wilkinson, M., & Gécz, J. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.016 · Cited by 167
Elborn, J. S., Ramsey, B. W., Boyle, M. P., Konstan, M. W., Huang, X., Marigowda, G., Waltz, D., & Wainwright, C. E. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30121-7 · Cited by 165
Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis
Prayle, A., Watson, A., Fortnum, H., & Smyth, A. (2010) · Thorax · doi:10.1136/thx.2009.131532 · Cited by 162
Xue, X., Mutyam, V., Tang, L., Biswas, S., Du, M., Jackson, L. A., Dai, Y., Белахов, В. В., Shalev, M., Chen, F., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0282oc · Cited by 161
Pranke, I. M., Hatton, A., Simonin, J., Jais, J. P., Le Pimpec-Barthes, F., Carsin, A., Bonnette, P., Fayon, M., Stremler-Le Bel, N., Grenet, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07504-1 · Cited by 161
Sermet-Gaudelus, I., Renouil, M., Fajac, A., Bidou, L., Parbaille, B., Pierrot, S., Davy, N., Bismuth, E., Reinert, P., Lenoir, G., et al. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-5 · Cited by 160
Rescue of nonsense mutations by amlexanox in human cells
Gonzalez-Hilarion, S., Beghyn, T., Jia, J., Debreuck, N., Berte, G., Mamchaoui, K., Mouly, V., Gruenert, D. C., Déprez, B., & Lejeune, F. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-58 · Cited by 159
Glozman, R., Okiyoneda, T., Mulvihill, C. M., Rini, J. M., Barrière, H., & Lukács, G. L. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200808124 · Cited by 156
Sawicki, G. S., Ren, C. L., Konstan, M. W., Millar, S. J., Pasta, D. J., & Quittner, A. L. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.12.009 · Cited by 154
Stallings, V. A., Sainath, N. N., Bensignor, M. O., Bertolaso, C., & Schall, J. I. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.05.018 · Cited by 151
Harris, J. K., Wagner, B. D., Zemanick, E. T., Robertson, C. E., Stevens, M. J., Heltshe, S. L., Rowe, S. M., & Sagel, S. D. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201907-493oc · Cited by 150
Durmowicz, A. G., Lim, R., Rogers, H. L., Rosebraugh, C. J., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201708-668ps · Cited by 148
Rosenfeld, M., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Chilvers, M. A., Higgins, M., Tian, S., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.009 · Cited by 147
Pedemonte, N., Sonawane, N. D., Taddei, A., Hu, J., Zegarra‐Moran, O., Suen, Y. F., Robins, L. I., Dicus, C. W., Willenbring, D., Nantz, M. H., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.010959 · Cited by 146
Graeber, S. Y., Dopfer, C., Naehrlich, L., Gyulumyan, L., Scheuermann, H., Hirtz, S., Wege, S., Mairbäurl, H., Dorda, M., Hyde, R., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-1983oc · Cited by 146
McNamara, J., McColley, S. A., Marigowda, G., Liu, F., Tian, S., Owen, C. A., Stiles, D., Li, C., Waltz, D. A., Wang, L. T., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30460-0 · Cited by 144
He, L., Kota, P. B., Aleksandrov, A. A., Cui, L., Jensen, T., Dokholyan, N. V., & Riordan, J. R. (2012) · The FASEB Journal · doi:10.1096/fj.12-216119 · Cited by 141
Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines
Haws, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H. A., Law, T. C., Xia, Y., Nguyen, H., & Wine, J. J. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.270.5.c1544 · Cited by 138
Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis
Burgel, P., Munck, À., Durieu, I., Chiron, R., Mély, L., Prévötat, A., Murris‐Espin, M., Porzio, M., Abély, M., Reix, P., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1227oc · Cited by 138
Influence of cell background on pharmacological rescue of mutant CFTR
Pedemonte, N., Tomati, V., Sondo, E., & Galietta, L. J. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00404.2009 · Cited by 136
Structure-guided combination therapy to potently improve the function of mutant CFTRs
Veit, G., Xu, H., Dreano, E., Avramescu, R. G., Bagdany, M., Beitel, L. K., Roldan, A., Hancock, M. A., Lay, C., Li, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0200-x · Cited by 134
Mechanisms of CFTR Folding at the Endoplasmic Reticulum
Kim, S. J., & Skach, W. R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00201 · Cited by 131
Westwood, M. E., Joore, M. A., Whiting, P. F., van Asselt, A. D. I., Ramaekers, B. L. T., Armstrong, N., Misso, K., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18320 · Cited by 130
Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo
Illek, B., & Fischer, H. (1998) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1998.275.5.l902 · Cited by 114
The psychological burden of cystic fibrosis
Quittner, A. L., Saez-Flores, E., & Barton, J. D. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000244 · Cited by 110
Adherence to therapies in cystic fibrosis: a targeted literature review
Narayanan, S., Mainz, J. G., Gala, S., Tabori, H., & Grossoehme, D. H. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1280399 · Cited by 109
Ziaian, T., Sawyer, M. G., Reynolds, K. E., Carbone, J. A., Clark, J. J., Baghurst, P., Couper, J., Kennedy, D., Martin, A. J., STAUGAS, R., et al. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00943.x · Cited by 108
Molinski, S. V., Ahmadi, S., Ip, W., Ouyang, H., Villella, A., Miller, J. P., Lee, P., Kulleperuma, K., Du, K., Paola, M. D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607137 · Cited by 107
Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
Kelly, A. T., León, D. D. D., Sheikh, S., Camburn, D. M., Kubrak, C., Peleckis, A. J., Stefanovski, D., Hadjiliadis, D., Rickels, M. R., & Rubenstein, R. C. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1018oc · Cited by 107
Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies
Brewington, J. J., Filbrandt, E. T., LaRosa, F. J., Moncivaiz, J. D., Ostmann, A. J., Strecker, L. M., & Clancy, J. P. (2018) · JCI Insight · doi:10.1172/jci.insight.99385 · Cited by 106
Taylor-Cousar, J. L., Mall, M. A., Ramsey, B. W., McKone, E. F., Tullis, E., Marigowda, G., McKee, C. M., Waltz, D., Moskowitz, S. M., Savage, J., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00082-2019 · Cited by 105
Whiting, P. F., Al, M., Burgers, L., Westwood, M. E., Ryder, S., Hoogendoorn, M., Armstrong, N., Allen, A., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18180 · Cited by 105
Sampson, H. M., Robert, R., Liao, J., Matthes, E., Carlile, G. W., Hanrahan, J. W., & Thomas, D. Y. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.11.016 · Cited by 105
Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis
Romani, L. R., Oikonomou, V., Moretti, S., Iannitti, R. G., D’Adamo, M. C., Villella, V. R., Pariano, M., Sforna, L., Borghi, M., Bellet, M. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4305 · Cited by 104
McCague, A. F., Raraigh, K. S., Pellicore, M. J., Davis-Marcisak, E. F., Evans, T. A., Han, S. T., Lu, Z., Joynt, A. T., Sharma, N., Castellani, C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201901-0145oc · Cited by 104
Frost, F. J., Nazareth, D. S., Charman, S. C., Winstanley, C., & Walshaw, M. J. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201902-122oc · Cited by 102
Sergeev, V., Chou, F. Y., Lam, G. Y., Hamilton, C. M., Wilcox, P., & Quon, B. S. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201909-671cme · Cited by 101
Barry, P. J., Plant, B. J., Nair, A., Bicknell, S. R., Simmonds, N. J., Bell, N., Shafi, N., Daniels, T. W. V., Shelmerdine, S. C., Felton, I. C., et al. (2014) · CHEST Journal · doi:10.1378/chest.13-2397 · Cited by 99
Borowitz, D., Lubarsky, B., Wilschanski, M. A., Munck, À., Gelfond, D., Bodewes, F. A. J. A., & Schwarzenberg, S. J. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3834-2 · Cited by 99
Xue, X., Mutyam, V., Thakerar, A., Mobley, J. A., Bridges, R. J., Rowe, S. M., Keeling, K. M., & Bedwell, D. M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx196 · Cited by 99
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators
Han, S. T., Rab, A., Pellicore, M. J., Davis-Marcisak, E. F., McCague, A. F., Evans, T. A., Joynt, A. T., Lu, Z., Cai, Z., Raraigh, K. S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121159 · Cited by 98
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Habib, A.-R. R., Kajbafzadeh, M., Desai, S., Yang, C. L., Skolnik, K., & Quon, B. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43652-2 · Cited by 98
Haggie, P. M., Phuan, P., Tan, J., Xu, H., Avramescu, R. G., Perdomo, D., Zlock, L. T., Nielson, D. W., Finkbeiner, W. E., Lukács, G. L., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.764720 · Cited by 97
Chappe, V. M., Hinkson, D. A. R., Zhu, T., Chang, X.-B., Riordan, J. R., & Hanrahan, J. W. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.035790 · Cited by 96
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening
Kalid, O., Mense, M., Fischman, S., Shitrit, A., Bihler, H. J., Ben‐Zeev, E., Schutz, N. C., Pedemonte, N., Thomas, P., Bridges, R. J., et al. (2010) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-010-9390-0 · Cited by 94
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics
Strug, L. J., Gonska, T. Y., He, G., Keenan, K., Ip, W., Boëlle, P., Fan, L., Panjwani, N., Gong, J., Li, W., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw290 · Cited by 94
Hudson, R. P., Dawson, J. E., Chong, P. A., Yang, Z. W., Millen, L., Thomas, P., Brouillette, C. G., & Forman-Kay, J. D. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108373 · Cited by 93
Awatade, N. T., Wong, S. L., Hewson, C. K., Fawcett, L. K., Kicic, A., Jaffe, A., & Waters, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01429 · Cited by 92
Tosco, A., De Gregorio, F., Esposito, S., De Stefano, D., Sana, I., Ferrari, E., Sepe, A., Salvadori, L., Buonpensiero, P., Di Pasqua, A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.22 · Cited by 92
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
Rowe, S. M., McColley, S. A., Rietschel, E., Li, X., Bell, S. C., Konstan, M. W., Marigowda, G., Waltz, D., & Boyle, M. P. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201609-689oc · Cited by 92
Ahner, A., Gong, X., Schmidt, B. Z., Peters, K. W., Rabeh, W. M., Thibodeau, P. H., Lukács, G. L., & Frizzell, R. A. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-09-0678 · Cited by 91
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease
Moore, P. J., & Tarran, R. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1501361 · Cited by 91
Ronan, N. J., Einarsson, G. G., Twomey, ., Mooney, D., Mullane, D., NíChróinín, M., O'Callaghan, G. P., Shanahan, F., Murphy, D. M., O’Connor, O. J., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.10.005 · Cited by 90
Mutyam, V., Du, M., Xue, X., Keeling, K. M., White, E. L., Bostwick, J. R., Rasmussen, L. A., Liu, B., Mazur, M., Hong, J. S., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0154oc · Cited by 87
Harbeson, S. L., Morgan, A. J., Liu, J. F., Aslanian, A. M., Nguyen, S., Bridson, G. W., Brummel, C. L., Wu, L., Tung, R. D., Pilja, L., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241497 · Cited by 87
O’Neal, W. K., & Knowles, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021329 · Cited by 87
O’Sullivan, B. P., Orenstein, D. M., & Milla, C. E. (2013) · JAMA · doi:10.1001/jama.2013.278129 · Cited by 85
Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase
Okiyoneda, T., Veit, G., Sakai, R., Aki, M., Fujihara, T., Higashi, M., Susuki-Miyata, S., Miyata, M., Fukuda, N., Yoshida, A., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.001 · Cited by 82
Giuliano, K. A., Wachi, S., Drew, L., Dukovski, D., Green, O., Bastos, C., Cullen, M. D., Hauck, S. I., Tait, B. D., Muñoz, B., et al. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217729790 · Cited by 81
Groot, K. M. D. W., Janssens, H. M., van Uum, R. T., Dekkers, J. F., Berkers, G., Vonk, A. M., Kruisselbrink, E., Oppelaar, H., Vries, R. G. J., Clevers, H. C., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.02529-2017 · Cited by 80
Donaldson, S. H., Laube, B. L., Corcoran, T. E., Bhambhvani, P. G., Zeman, K. L., Ceppe, A., Zeitlin, P. L., Mogayzel, P. J., Boyle, M., Locke, L. W., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122695 · Cited by 79
Stanton, B. A., Coutermarsh, B., Barnaby, R., & Hogan, D. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127742 · Cited by 78
Resolution of Cystic Fibrosis–related Diabetes with Ivacaftor Therapy
Hayes, D., McCoy, K., & Sheikh, S. I. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0882le · Cited by 78
Wang, X., Liu, B., Searle, X. B., Yeung, C. M., Bogdan, A. R., Greszler, S. N., Singh, A. K., Fan, Y., Swensen, A. M., Vortherms, T. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01339 · Cited by 78
Awatade, N. T., Uliyakina, I., Farinha, C. M., Clarke, L. A., Mendes, K., Solé, A., Pastor, J., Ramos, M. M. P., & Amaral, M. D. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.12.005 · Cited by 77
Schlander, M., Garattini, S. K., Holm, S., Kolominsky‐Rabas, P. L., Nord, E., Persson, U., Postma, M. J., Richardson, J. R. J., Simoens, S., Morales, O. D. S., et al. (2014) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.34 · Cited by 77
Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides
Igreja, S., Clarke, L. A., Botelho, H. M., Marques, L., & Amaral, M. D. (2015) · Human Mutation · doi:10.1002/humu.22931 · Cited by 77
Rowe, S. M., Sloane, P. A., Tang, L. P., Backer, K., Mazur, M., Buckley-Lanier, J. A., Nudelman, I., Белахов, В. В., Bebők, Z., Schwiebert, E. M., et al. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0787-6 · Cited by 76
Taylor‐Cousar, J. L., Jain, M., Barto, T. L., Haddad, T., Atkinson, J. J., Tian, S., Tang, R., Marigowda, G., Waltz, D. A., & Pilewski, J. M. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.09.012 · Cited by 75
Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR
Keenan, M. M., Huang, L., Jordan, N. J., Wong, E., Cheng, Y., Valley, H. C., Mahiou, J., Liang, F., Bihler, H. J., Mense, M., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0316oc · Cited by 75
Donaldson, S. H., Solomon, G. M., Zeitlin, P. L., Flume, P. A., Casey, A. M. H., McCoy, K., Zemanick, E. T., Mandagere, A., Troha, J. M., Shoemaker, S. A., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.01.009 · Cited by 74
Socioeconomic status and health outcomes: cystic fibrosis as a model
Oates, G. R., & Schechter, M. S. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1196140 · Cited by 73
Sondo, E., Falchi, F., Caci, E., Ferrera, L., Giacomini, E., Pesce, E., Tomati, V., Bertozzi, S. M., Goldoni, L., Armirotti, A., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.04.010 · Cited by 73
Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor
Siracusa, C. M., Ryan, J. L., Burns, L., Wang, Y., Zhang, N., Clancy, J. P., & Drotar, D. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.05.009 · Cited by 71
EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1
Lobo, M. J., Amaral, M. D., Zaccolo, M., & Farinha, C. M. (2016) · Journal of Cell Science · doi:10.1242/jcs.185629 · Cited by 70
Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation
Trimble, A. T., & Donaldson, S. H. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.09.006 · Cited by 70
The Australian Cystic Fibrosis Data Registry Annual Report, 2017
Ruseckaite, R., Ahern, S., Ranger, T. A., TACEY, M. A., Dean, J. T., Gardam, M., Bell, S. C., & Burke, N. (2021) · Cited by 70
Walker, S., Flume, P. A., McNamara, J., Solomon, M. P., Chilvers, M. A., Chmiel, J. F., Harris, R. S., Haseltine, E. L., Stiles, D., Li, C., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.009 · Cited by 70
Matthes, E., Goepp, J., Carlile, G. W., Luo, Y., Dejgaard, K., Billet, A., Robert, R., Thomas, D. Y., & Hanrahan, J. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13365 · Cited by 69
A Stabilizing Influence: CAL PDZ Inhibition Extends the Half‐Life of ΔF508‐CFTR
Cushing, P. R., Vouillème, L., Pellegrini, M., Boisguérin, P., & Madden, D. R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005585 · Cited by 69
Tsabari, R., Elyashar, H. I., Cymberknowh, M. C., Breuer, O., Armoni, S., Livnat, G., Kerem, E., & Zangen, D. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.10.012 · Cited by 69
Phuan, P., Veit, G., Tan, J. A., Roldán, A., Finkbeiner, W. E., Lukács, G. L., & Verkman, A. S. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092478 · Cited by 69
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 69
McGarry, M. E., Illek, B., Ly, N. P., Zlock, L. T., Olshansky, S., Moreno, C., Finkbeiner, W. E., & Nielson, D. W. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23659 · Cited by 68
Current and emerging comorbidities in cystic fibrosis
Ronan, N. J., Elborn, J. S., & Plant, B. J. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.05.011 · Cited by 68
A common mechanism for CFTR potentiators
Yeh, H., Sohma, Y., Conrath, K., & Hwang, T. (2017) · The Journal of General Physiology · doi:10.1085/jgp.201711886 · Cited by 68
Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770
Yeh, H., Qiu, L., Sohma, Y., Conrath, K., Zou, X.-Q., & Hwang, T. (2019) · The Journal of General Physiology · doi:10.1085/jgp.201912360 · Cited by 68
Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids
Dekkers, J. F., Gondra, R. A. G., Kruisselbrink, E., Vonk, A. M., Janssens, H. M., Groot, K. M. D. W., van der Ent, C. K., & Beekman, J. M. (2016) · European Respiratory Journal · doi:10.1183/13993003.01192-2015 · Cited by 67
Economic Modeling Considerations for Rare Diseases
Pearson, I. V., Rothwell, B., Olaye, A., & Knight, C. (2018) · Value in Health · doi:10.1016/j.jval.2018.02.008 · Cited by 67
Dřevínek, P., Pressler, T., Cipolli, M., Boeck, K. D., Schwarz, C., Bouisset, F., Boff, M., Henig, N. R., Paquette-Lamontagne, N., Montgomery, S., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.014 · Cited by 67
Phuan, P., Son, J., Tan, J., Li, C. J., Musante, I., Zlock, L. T., Nielson, D. W., Finkbeiner, W. E., Kurth, M. J., Galietta, L. J. V., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.05.010 · Cited by 66
Farrell, P. M., Férec, C., Maçek, M., Frischer, T., Renner, S., Riss, K. C., Barton, D. E., Repetto, T., Tzetis, M., Giteau, K., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0234-z · Cited by 65
Moniz, S., Sousa, M., Moraes, B. J., Mendes, A. I., Palma, M., Barreto, C., Fragata, J., Amaral, M. D., & Matos, P. (2012) · ACS Chemical Biology · doi:10.1021/cb300484r · Cited by 64
The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis
Sondo, E., Caci, E., & Galietta, L. J. V. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.022 · Cited by 64
der Plas, S. E. V., Kelgtermans, H., Munck, T. D., Martina, S. L. X., Dropsit, S., Quinton, E. M., Blieck, A. D., Joannesse, C., Tomašković, L., Jans, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01288 · Cited by 64
Sharma, N., Evans, T. A., Pellicore, M. J., Davis-Marcisak, E. F., Aksit, M. A., McCague, A. F., Joynt, A. T., Lu, Z., Han, S. T., Anzmann, A. F., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007723 · Cited by 64
Pereira, S. V.-N., Ribeiro, J. D., Ribeiro, A. F., Bertuzzo, C. S., & Marson, F. A. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-42404-6 · Cited by 64
Cited by
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 366
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344
Scotet, V., L’Hostis, C., & Férec, C. (2020) · Genes · doi:10.3390/genes11060589 · Cited by 317
Zemanick, E. T., Taylor-Cousar, J. L., Davies, J., Gibson, R. L., Mall, M. A., McKone, E. F., McNally, P., Ramsey, B. W., Rayment, J. H., Rowe, S. M., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202102-0509oc · Cited by 305
Metadata
- Authors
- Lopes-Pacheco, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-21
- Volume
- 10
- Pages
- 1662-1662
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3008025512
- Cited by
- 535
- References
- 287
- FWCI
- 37.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.